 |
 |
||||||||||
 |
 |
|
|||||||||
 |
 |
 |
|
||||||||
 |
|
||||||||||
 |
|
||||||||||
 |
|
||||||||||
 |
|
||||||||||
 |
|
||||||||||
 |
 |
 |
 |
|
|||||||
|
OncoMed’s first clinical trial, using an internally discovered and developed monoclonal antibody, OMP-21M18, is now open for patient enrollment. This antibody targets a pathway critical for cancer stem cells and will ultimately be tested in several common solid tumors. Details of this Phase I trial may be found at ClinicalTrials.gov. GlaxoSmithKline And OncoMed Pharmaceuticals Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics |
|
||||||||||
 |
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. We are leveraging our understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. |
 |
|
||||||||
 |
|
||||||||||
|
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy. read the article Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. read the article Phenotypic characterization of human colorectal cancer stem cells. read the article more publications... |
|
||||||||||
| OncoMed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City, CA 94063 Copyright © 2007 |
 |
|
|||||||||
 |
Home | About Us | Research | Careers | News | Contact Us |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|